What studies of triphala found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group and the placebo trial (very low certainty): 3 of 4 findings are C.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Triphala might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Triphala · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Breathlessness1 study · 37 people took triphala Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (37 in all); effect size 0.08 (very small); the benefit is very small.
The placebo trial78 randomised · 37 analysed · 8 weeks · 1000 mg/day, five days per week for eight weeks
Breathlessness improved more than in the comparison group.
The evidence is very uncertain about the effect of triphala on breathlessness in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (37 in all)
- Effect size 0.08 (very small)
- The benefit is very small
How big was the difference?
0.08, very small. The effect size compares triphala with placebo.
See the 1 study
-
- People in the study
- 78 randomised · 37 analysed
- Dose
- 1000 mg/day, five days per week for eight weeks
- Outcome
- respiratory symptoms (breathlessness, cough)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Fatigue1 study · 37 people took triphala Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (37 in all).
Studies with no comparison group78 randomised · 37 analysed · 8 weeks · 1000 mg/day, five days per week for eight weeks
Fatigue improved.
The evidence is very uncertain about the effect of triphala on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (37 in all)
See the 1 study
-
- People in the study
- 78 randomised · 37 analysed
- Dose
- 1000 mg/day, five days per week for eight weeks
- Outcome
- fatigue
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 37 people took triphala Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (37 in all); effect size 0.09 (very small); the benefit is very small.
The placebo trial78 randomised · 37 analysed · 8 weeks · 1000 mg/day, five days per week for eight weeks
Pain improved more than in the comparison group.
The evidence is very uncertain about the effect of triphala on pain in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (37 in all)
- Effect size 0.09 (very small)
- The benefit is very small
How big was the difference?
0.09, very small. The effect size compares triphala with placebo.
See the 1 study
-
- People in the study
- 78 randomised · 37 analysed
- Dose
- 1000 mg/day, five days per week for eight weeks
- Outcome
- headache
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Cognition (brain fog)1 study · 37 people took triphala Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 37 people found no clear difference; a small benefit can't be ruled out; effect size 0.01 (very small).
The placebo trial78 randomised · 37 analysed · 8 weeks · 1000 mg/day, five days per week for eight weeks
No clear difference in cognition (brain fog).
The evidence is very uncertain about the effect of triphala on cognition (brain fog) in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 37 people found no clear difference; a small benefit can't be ruled out
- Effect size 0.01 (very small)
How big was the difference?
0.01, very small. The effect size compares triphala with placebo.
See the 1 study
-
- People in the study
- 78 randomised · 37 analysed
- Dose
- 1000 mg/day, five days per week for eight weeks
- Outcome
- cognitive impairment (memory difficulties, lack of concentration)
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Low
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Side effects
Stopping because of side effects2 studies
Despite these occurrences, no participants discontinued the exercise program
Anti-Inflammatory and Antioxidant Effects of HIIT in Individuals with Long COVID: Insights into the Potential Role of Triphala. (2025)One participant from the placebo group (2.63%) and three from the Triphala group (7.50%) withdrew due to non-compliance with the 8-week supplementation protocol
Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial. (2025)
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
500 to 1000 mg at the start
- 2Top dose
Most often 500 mg (1 of 2 studies)
Doses across 2 studies
500 to 1000 mg.
Each study’s dose, as printed
- 500 mg twice daily, totaling 1000 mg/day Anti-Inflammatory and Antioxidant Effects of HIIT in Individuals with Long COVID: Insights into the Potential Role of Triphala. (2025)
- 1000 mg/day, five days per week for eight weeks Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial. (2025)
All papers
- Anti-Inflammatory and Antioxidant Effects of HIIT in Individuals with Long COVID: Insights into the Potential Role of Triphala.2025 · placebo trial · 112 randomised · 104 analysed
Summary
This randomized controlled trial enrolled 112 people with long COVID and post-exertional malaise; 8 did not complete the intervention (5 contracted COVID-19, 1 had unrelated health issues, 2 were unable to attend the post-intervention assessment), and 104 were included in the final analysis. Participants were allocated to a control group (no structured exercise plus placebo capsule), a HIIT group (supervised cycling HIIT three times per week for 8 weeks), or a combined group (the same HIIT plus Triphala 500 mg twice daily, totaling 1000 mg/day, for 8 weeks). The paper reports that, after the 8-week intervention, IFN-γ, TNF-α, MDA, protein carbonyls, and rating of perceived exertion showed significant reductions in both the HIIT and combined groups, with no significant differences between the two; the control group showed no significant changes for IFN-γ, TNF-α, MDA, or protein carbonyls. SOD activity increased in all groups, including the control group, with no between-group differences. Breathlessness decreased in both the HIIT and combined groups with no significant between-group difference; leg fatigue remained unchanged and comparable. No serious adverse events were reported. Minor adverse events—leg muscle fatigue, dizziness, and transient hypotension—were observed in four participants during the final week of the intervention, specifically during the fourth HIIT cycle; no participants discontinued the exercise program. The paper does not report the recruitment setting.
- Ameliorative Effects of Triphala Supplementation on Oxidative Stress and Inflammation in Individuals with Post-COVID-19 Condition: A Preliminary Randomized Controlled Trial.2025 · placebo trial · 78 randomised · 37 analysed
Summary
This preliminary randomized, double-blind, placebo-controlled trial evaluated whether Triphala changes oxidative stress, antioxidant activity and systemic inflammation in 78 people with post-COVID-19 condition in Chonburi Province, Thailand. Participants were randomly assigned to placebo (n = 38) or Triphala (1000 mg/day; n = 40), taken 5 days per week for 8 weeks; 37 in each group completed. MDA, protein carbonyl, SOD, IFN-γ and TNF-α were measured before and after supplementation. In the Triphala group, MDA (P = .026), protein carbonyl (P = .017), IFN-γ (P = .038) and TNF-α (P < .001) decreased, and SOD activity increased (P = .008); in the placebo group only SOD activity increased (P < .001). No statistically significant differences were observed between groups in any primary outcome. Mean change in protein carbonyl (0.00 vs −0.02 nmol/mg protein; P = .048) and TNF-α (−0.05 vs −0.46 pg/mL; P = .001) was significantly greater in the Triphala group. No adverse events were reported as related to either placebo or Triphala supplementation; one placebo participant (2.63%) and three Triphala participants (7.50%) withdrew due to non-compliance. The authors state that most primary outcomes did not show statistically significant between-group differences and call for larger, longer studies.
- The role of herbal medicine in supporting cognitive dysfunction associated with long COVID: Review2026 · review
Summary
This review examined herbal medicine for cognitive dysfunction associated with Post-COVID-19 Condition (PCC). The search covered PubMed, Scopus, ProQuest, and Cochrane for English-language papers with search parameters between January 2020 and November 2025; five primary clinical studies were included. These were a case study series of 5 patients given EGb761® (Ginkgo biloba); a single case of one 55-year-old female given Hochuekkito with other treatments; a prospective pilot study of 45 participants given Bojungikgi-tang, Kyungok-go, or Cheonwangbosim-dan; a retrospective cohort of 47 patients given Traditional Chinese HMs; and an RCT of 78 participants comparing Triphala with placebo. Durations varied across studies. Outcomes included cognitive severity and cognitive tests, fatigue, respiratory symptoms, emotional distress, oxidative stress, inflammatory biomarkers, and self-report questionnaires. EGb761® appeared to substantially improve cognition in all five patients, with mean time to improvement 10.6 weeks (range 7–16 weeks). The single case reported NRS reducing from 5 to 0 and BFI from 7.0 to 0.5, and TMT-A improving by 10 s. Kim et al. reported no significant between-group cognitive change (p = 0.1225), with 14 participants lost to follow-up. Hsieh et al. reported fatigue and respiratory improvements, but emotional distress changes were not significant. Intakhiao et al. found no significant between-group change in cognitive function; fatigue and headache improved in both groups, and respiratory symptoms were lower than placebo (p = 0.025). No significant adverse events were reported in the Zifko, Kim, or Intakhiao studies. Worsening or stopping was not reported. The authors state the evidence is heterogeneous and methodologically limited.